Unicycive Therapeutics Inc Total Assets
Unicycive Therapeutics Inc total assets. Based on the latest financial reports, Unicycive Therapeutics Inc (UNCY) holds total assets worth $72.03 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see UNCY market cap for the company's overall valuation and market capitalisation.
Total Assets of Unicycive Therapeutics Inc (2018–2025)
Total assets of Unicycive Therapeutics Inc from 2018 to 2025. This chart illustrates how Unicycive Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Unicycive Therapeutics Inc share price for real-time trading data and today's change.
Unicycive Therapeutics Inc - Asset Composition Analysis
Unicycive Therapeutics Inc Total Assets Breakdown (December 2025)
Unicycive Therapeutics Inc total assets breakdown as of December 2025. Unicycive Therapeutics Inc's total assets of $72.03 Million consist of 99.7% current assets and 0.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 59.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Unicycive Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Unicycive Therapeutics Inc (UNCY) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Unicycive Therapeutics Inc's current assets represent 99.7% of total assets in 2025, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 59.4% of total assets in 2025, down from 86.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Unicycive Therapeutics Inc Competitors by Total Assets
Key competitors of Unicycive Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Unicycive Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.81 | 2.18 | 25.20 |
| Quick Ratio | 3.81 | 2.18 | 25.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $52.62 Million | $15.96 Million | $19.00 Million |
Unicycive Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Unicycive Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.78 |
| Latest Market Cap to Assets Ratio | 1.95 |
| Asset Growth Rate (YoY) | 55.2% |
| Total Assets | $49.13 Million |
| Market Capitalization | $95.60 Million USD |
Valuation Analysis
Above Book Valuation: The market values Unicycive Therapeutics Inc's assets above their book value (1.95x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Unicycive Therapeutics Inc's assets grew by 55.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Unicycive Therapeutics Inc (2018–2025)
The table below shows the annual total assets of Unicycive Therapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $49.13 Million | +55.16% |
| 2024-12-31 | $31.67 Million | +123.16% |
| 2023-12-31 | $14.19 Million | +403.58% |
| 2022-12-31 | $2.82 Million | -84.97% |
| 2021-12-31 | $18.74 Million | +9088.24% |
| 2020-12-31 | $204.00K | +973.68% |
| 2019-12-31 | $19.00K | -34.48% |
| 2018-12-31 | $29.00K | -- |
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester deriv… Read more